Switch to:
Also traded in: Austria, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.05
HSIC's Cash-to-Debt is ranked lower than
95% of the 60 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.66 vs. HSIC: 0.05 )
Ranked among companies with meaningful Cash-to-Debt only.
HSIC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.25 Max: 2.53
Current: 0.05
0.04
2.53
Equity-to-Asset 0.40
HSIC's Equity-to-Asset is ranked higher than
52% of the 58 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.41 vs. HSIC: 0.40 )
Ranked among companies with meaningful Equity-to-Asset only.
HSIC' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.51 Max: 0.67
Current: 0.4
0.21
0.67
Debt-to-Equity 0.52
HSIC's Debt-to-Equity is ranked higher than
51% of the 53 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.48 vs. HSIC: 0.52 )
Ranked among companies with meaningful Debt-to-Equity only.
HSIC' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.12  Med: 0.29 Max: 1.54
Current: 0.52
0.12
1.54
Debt-to-EBITDA 1.51
HSIC's Debt-to-EBITDA is ranked higher than
67% of the 48 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.03 vs. HSIC: 1.51 )
Ranked among companies with meaningful Debt-to-EBITDA only.
HSIC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.48  Med: 0.76 Max: 1.51
Current: 1.51
0.48
1.51
Interest Coverage 17.72
HSIC's Interest Coverage is ranked higher than
58% of the 50 Companies
in the Global Medical Distribution industry.

( Industry Median: 10.55 vs. HSIC: 17.72 )
Ranked among companies with meaningful Interest Coverage only.
HSIC' s Interest Coverage Range Over the Past 10 Years
Min: 12.12  Med: 19.95 Max: 29.73
Current: 17.72
12.12
29.73
Piotroski F-Score: 5
Altman Z-Score: 4.27
Beneish M-Score: -2.38
WACC vs ROIC
8.01%
14.68%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 6.79
HSIC's Operating Margin % is ranked higher than
65% of the 60 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.74 vs. HSIC: 6.79 )
Ranked among companies with meaningful Operating Margin % only.
HSIC' s Operating Margin % Range Over the Past 10 Years
Min: 6.57  Med: 6.9 Max: 7.1
Current: 6.79
6.57
7.1
Net Margin % 4.52
HSIC's Net Margin % is ranked higher than
67% of the 60 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.81 vs. HSIC: 4.52 )
Ranked among companies with meaningful Net Margin % only.
HSIC' s Net Margin % Range Over the Past 10 Years
Min: 3.64  Med: 4.36 Max: 4.76
Current: 4.52
3.64
4.76
ROE % 19.22
HSIC's ROE % is ranked higher than
85% of the 59 Companies
in the Global Medical Distribution industry.

( Industry Median: 10.64 vs. HSIC: 19.22 )
Ranked among companies with meaningful ROE % only.
HSIC' s ROE % Range Over the Past 10 Years
Min: 13.24  Med: 15.6 Max: 19.22
Current: 19.22
13.24
19.22
ROA % 7.96
HSIC's ROA % is ranked higher than
88% of the 60 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.48 vs. HSIC: 7.96 )
Ranked among companies with meaningful ROA % only.
HSIC' s ROA % Range Over the Past 10 Years
Min: 6.93  Med: 7.74 Max: 8.37
Current: 7.96
6.93
8.37
ROC (Joel Greenblatt) % 42.04
HSIC's ROC (Joel Greenblatt) % is ranked higher than
80% of the 59 Companies
in the Global Medical Distribution industry.

( Industry Median: 22.84 vs. HSIC: 42.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HSIC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 42.04  Med: 48.65 Max: 51.27
Current: 42.04
42.04
51.27
3-Year Revenue Growth Rate 9.00
HSIC's 3-Year Revenue Growth Rate is ranked higher than
53% of the 49 Companies
in the Global Medical Distribution industry.

( Industry Median: 8.60 vs. HSIC: 9.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HSIC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -12.6  Med: 9.25 Max: 262.4
Current: 9
-12.6
262.4
3-Year EBITDA Growth Rate 7.70
HSIC's 3-Year EBITDA Growth Rate is ranked lower than
51% of the 43 Companies
in the Global Medical Distribution industry.

( Industry Median: 7.90 vs. HSIC: 7.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
HSIC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 3.7  Med: 11.5 Max: 38.9
Current: 7.7
3.7
38.9
3-Year EPS without NRI Growth Rate 7.90
HSIC's 3-Year EPS without NRI Growth Rate is ranked lower than
52% of the 42 Companies
in the Global Medical Distribution industry.

( Industry Median: 10.10 vs. HSIC: 7.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
HSIC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -7.2  Med: 11.95 Max: 70.4
Current: 7.9
-7.2
70.4
GuruFocus has detected 1 Warning Sign with Henry Schein Inc HSIC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HSIC's 30-Y Financials

Financials (Next Earnings Date: 2018-02-21)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

HSIC Guru Trades in Q4 2016

Joel Greenblatt 127,262 sh (New)
Jim Simons 474,006 sh (New)
George Soros 2,200 sh (New)
Steven Cohen 212,300 sh (+60.47%)
Paul Tudor Jones 2,300 sh (+4.55%)
Mario Gabelli 156,837 sh (-1.37%)
Ken Fisher 462,101 sh (-3.62%)
Ron Baron 359,595 sh (-4.87%)
Jeremy Grantham 7,431 sh (-44.35%)
» More
Q1 2017

HSIC Guru Trades in Q1 2017

Steven Cohen 322,763 sh (+52.03%)
Ron Baron 359,595 sh (unchged)
Jeremy Grantham Sold Out
George Soros Sold Out
Mario Gabelli 154,747 sh (-1.33%)
Ken Fisher 436,289 sh (-5.59%)
Jim Simons 313,606 sh (-33.84%)
Paul Tudor Jones 1,462 sh (-36.43%)
Joel Greenblatt 56,966 sh (-55.24%)
» More
Q2 2017

HSIC Guru Trades in Q2 2017

Ron Baron 360,195 sh (+0.17%)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Ken Fisher 423,469 sh (-2.94%)
Mario Gabelli 149,297 sh (-3.52%)
Jim Simons 67,106 sh (-78.60%)
Steven Cohen 50,500 sh (-84.35%)
» More
Q3 2017

HSIC Guru Trades in Q3 2017

Paul Tudor Jones 8,848 sh (New)
Steven Cohen 854,945 sh (+746.48%)
Ken Fisher 844,106 sh (-0.33%)
Mario Gabelli 282,468 sh (-5.40%)
Ron Baron 665,430 sh (-7.63%)
Jim Simons 8,812 sh (-93.43%)
» More
» Details

Insider Trades

Latest Guru Trades with HSIC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-09-30 Reduce -0.33%$79.14 - $92.85 $ 69.12-21%844,106
Ron Baron 2017-09-30 Reduce -7.63%0.03%$79.14 - $92.85 $ 69.12-21%665,430
Mario Gabelli 2017-09-30 Reduce -5.40%0.01%$79.14 - $92.85 $ 69.12-21%282,468
Ken Fisher 2017-06-30 Reduce -2.94%$83.78 - $93.29 $ 69.12-22%846,938
Ron Baron 2017-06-30 Add 0.17%$83.78 - $93.29 $ 69.12-22%720,390
Mario Gabelli 2017-06-30 Reduce -3.52%0.01%$83.78 - $93.29 $ 69.12-22%298,594
Joel Greenblatt 2017-06-30 Sold Out 0.12%$83.78 - $93.29 $ 69.12-22%0
Ken Fisher 2017-03-31 Reduce -5.59%0.01%$75.86 - $86.77 $ 69.12-16%872,578
Mario Gabelli 2017-03-31 Reduce -1.33%$75.86 - $86.77 $ 69.12-16%309,494
Joel Greenblatt 2017-03-31 Reduce -55.24%0.14%$75.86 - $86.77 $ 69.12-16%113,932
George Soros 2017-03-31 Sold Out 0.01%$75.86 - $86.77 $ 69.12-16%0
Ken Fisher 2016-12-31 Reduce -3.62%0.01%$73.52 - $81.56 $ 69.12-10%924,202
Ron Baron 2016-12-31 Reduce -4.87%0.02%$73.52 - $81.56 $ 69.12-10%719,190
Mario Gabelli 2016-12-31 Reduce -1.37%$73.52 - $81.56 $ 69.12-10%313,674
Joel Greenblatt 2016-12-31 New Buy0.25%$73.52 - $81.56 $ 69.12-10%254,524
George Soros 2016-12-31 New Buy0.01%$73.52 - $81.56 $ 69.12-10%4,400
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Distribution » Medical Distribution    NAICS: 423450    SIC: 5047
Compare:HKSE:01099, SHSE:601607, NYSE:ABC, XKRX:091990, NYSE:CAH, SHSE:600056, TSE:7459, SZSE:200028, SZSE:002589, NAS:PDCO, LSE:UDG, NYSE:PBH, SHSE:600090, NZSE:EBO, LSE:CLIN, NYSE:OMI, SHSE:603368, SHSE:600763, SZSE:002551, TSE:7476 » details
Traded in other countries:HSIC.Austria, HS2.Germany,
Headquarter Location:USA
Henry Schein Inc is a provider of healthcare products and services to office-based dental, animal health and medical practitioners. The company also serves dental laboratories, government and institutional health care clinics.

Henry Schein is one of the largest wholesalers of medical products, equipment, and devices in the United States. The firm has a focus on three major markets: Dental Practice, Medical products, and Animal Health (vet and production animal). It also offers dental practice management products that include software products, technical, financial, and educational services to thousands of dental practices throughout North America. The firm is also a major supplier of animal health products to vets and production companies globally.

Guru Investment Theses on Henry Schein Inc

Baron Funds Comments on Henry Schein Inc. - Oct 21, 2016

Shares of Henry Schein, Inc. (NASDAQ:HSIC), a global distributor of dental, medical, and animal health products, declined after reporting an unexpected slowdown in its North American dental and equipment sales. No specific reasons for the slowdown have emerged, and we believe that it is too early to extrapolate a trend. While performance in other divisions was solid, Schein’s earnings guidance was revised downward for the first time in several years. We are monitoring events but remain positive given, in our opinion, the company’s strong management, consistent performance, and large market opportunities.





From Baron Funds' Barron Asset Fund third-quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Henry Schein Inc

Henry Schein To Showcase Digital Solutions At Greater New York Dental Meeting, Nov. 26-29, 2017
AADOM Presents Fifth Annual Green Leader Award To Surf City Dental's Ruby Eaches
Consolidated Research: 2018 Summary Expectations for Take-Two, CME Group, Intuit, Henry Schein, VeriSign, and Regeneron – Fundamental Analysis, Key Performance Indications
Horizon Pharma Rises on Earnings Beat Company raised full-year guidance
Shares of Horizon Pharma PLC (NASDAQ:HZNP) gained in Monday trading after the company reported financial results for its third quarter. EPS of 26 cents beat analysts' expectations by four cents and revenue of $271.6 million beat estimates by $11.86 million but declined 0.8% year over year. Read more...
The Arnold P. Gold Foundation Announces Formation of Gold Corporate Council to Further Foundation's Mission of Humanism in Healthcare
Henry Schein Animal Health Creates Pet Diabetes Resource Center To Raise Awareness Of Disease's Risk Factors And Warning Signs
Henry Schein To Present At Two Conferences In November
Leidos Partnership for Defense Health Supports Advancement of Military Health System through Deployment of MHS GENESIS at Madigan Army Medical Center
Henry Schein To Webcast Third Quarter 2017 Conference Call On Monday, November 6, 2017 At 10:00 A.M. ET
Henry Schein To Showcase Leading Digital Solutions At The American Dental Association Annual Meeting

Ratios

vs
industry
vs
history
PE Ratio 19.92
HSIC's PE Ratio is ranked lower than
66% of the 47 Companies
in the Global Medical Distribution industry.

( Industry Median: 21.42 vs. HSIC: 19.92 )
Ranked among companies with meaningful PE Ratio only.
HSIC' s PE Ratio Range Over the Past 10 Years
Min: 12.02  Med: 22.37 Max: 30.67
Current: 19.92
12.02
30.67
Forward PE Ratio 17.73
HSIC's Forward PE Ratio is ranked lower than
87% of the 15 Companies
in the Global Medical Distribution industry.

( Industry Median: 13.55 vs. HSIC: 17.73 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 19.86
HSIC's PE Ratio without NRI is ranked lower than
63% of the 48 Companies
in the Global Medical Distribution industry.

( Industry Median: 21.66 vs. HSIC: 19.86 )
Ranked among companies with meaningful PE Ratio without NRI only.
HSIC' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.98  Med: 21.87 Max: 30.57
Current: 19.86
11.98
30.57
Price-to-Owner-Earnings 29.87
HSIC's Price-to-Owner-Earnings is ranked lower than
71% of the 34 Companies
in the Global Medical Distribution industry.

( Industry Median: 26.70 vs. HSIC: 29.87 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
HSIC' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.73  Med: 22.85 Max: 38.42
Current: 29.87
10.73
38.42
PB Ratio 3.60
HSIC's PB Ratio is ranked lower than
83% of the 59 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.33 vs. HSIC: 3.60 )
Ranked among companies with meaningful PB Ratio only.
HSIC' s PB Ratio Range Over the Past 10 Years
Min: 1.57  Med: 3.07 Max: 5.19
Current: 3.6
1.57
5.19
PS Ratio 0.90
HSIC's PS Ratio is ranked lower than
51% of the 59 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.03 vs. HSIC: 0.90 )
Ranked among companies with meaningful PS Ratio only.
HSIC' s PS Ratio Range Over the Past 10 Years
Min: 0.48  Med: 0.9 Max: 1.35
Current: 0.9
0.48
1.35
Price-to-Free-Cash-Flow 23.79
HSIC's Price-to-Free-Cash-Flow is ranked lower than
60% of the 25 Companies
in the Global Medical Distribution industry.

( Industry Median: 19.74 vs. HSIC: 23.79 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HSIC' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.19  Med: 19.54 Max: 31.3
Current: 23.79
9.19
31.3
Price-to-Operating-Cash-Flow 20.25
HSIC's Price-to-Operating-Cash-Flow is ranked lower than
59% of the 32 Companies
in the Global Medical Distribution industry.

( Industry Median: 17.77 vs. HSIC: 20.25 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HSIC' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.99  Med: 16.42 Max: 27.27
Current: 20.25
7.99
27.27
EV-to-EBIT 14.53
HSIC's EV-to-EBIT is ranked lower than
57% of the 47 Companies
in the Global Medical Distribution industry.

( Industry Median: 15.56 vs. HSIC: 14.53 )
Ranked among companies with meaningful EV-to-EBIT only.
HSIC' s EV-to-EBIT Range Over the Past 10 Years
Min: 6  Med: 12.4 Max: 20.7
Current: 14.53
6
20.7
EV-to-EBITDA 11.93
HSIC's EV-to-EBITDA is ranked lower than
60% of the 48 Companies
in the Global Medical Distribution industry.

( Industry Median: 11.09 vs. HSIC: 11.93 )
Ranked among companies with meaningful EV-to-EBITDA only.
HSIC' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.2  Med: 10.6 Max: 17
Current: 11.93
5.2
17
EV-to-Revenue 1.01
HSIC's EV-to-Revenue is ranked lower than
55% of the 60 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.09 vs. HSIC: 1.01 )
Ranked among companies with meaningful EV-to-Revenue only.
HSIC' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.5  Med: 0.9 Max: 1.4
Current: 1.01
0.5
1.4
PEG Ratio 2.31
HSIC's PEG Ratio is ranked lower than
59% of the 29 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.92 vs. HSIC: 2.31 )
Ranked among companies with meaningful PEG Ratio only.
HSIC' s PEG Ratio Range Over the Past 10 Years
Min: 0.56  Med: 2.1 Max: 3.32
Current: 2.31
0.56
3.32
Shiller PE Ratio 27.95
HSIC's Shiller PE Ratio is ranked lower than
60% of the 20 Companies
in the Global Medical Distribution industry.

( Industry Median: 27.77 vs. HSIC: 27.95 )
Ranked among companies with meaningful Shiller PE Ratio only.
HSIC' s Shiller PE Ratio Range Over the Past 10 Years
Min: 20.63  Med: 34.02 Max: 49.34
Current: 27.95
20.63
49.34
Current Ratio 1.55
HSIC's Current Ratio is ranked higher than
57% of the 56 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.48 vs. HSIC: 1.55 )
Ranked among companies with meaningful Current Ratio only.
HSIC' s Current Ratio Range Over the Past 10 Years
Min: 1.45  Med: 2.11 Max: 2.98
Current: 1.55
1.45
2.98
Quick Ratio 0.86
HSIC's Quick Ratio is ranked lower than
73% of the 56 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.04 vs. HSIC: 0.86 )
Ranked among companies with meaningful Quick Ratio only.
HSIC' s Quick Ratio Range Over the Past 10 Years
Min: 0.73  Med: 1.34 Max: 2.1
Current: 0.86
0.73
2.1
Days Inventory 65.52
HSIC's Days Inventory is ranked lower than
70% of the 56 Companies
in the Global Medical Distribution industry.

( Industry Median: 39.35 vs. HSIC: 65.52 )
Ranked among companies with meaningful Days Inventory only.
HSIC' s Days Inventory Range Over the Past 10 Years
Min: 54.28  Med: 60.27 Max: 68.85
Current: 65.52
54.28
68.85
Days Sales Outstanding 45.97
HSIC's Days Sales Outstanding is ranked higher than
72% of the 50 Companies
in the Global Medical Distribution industry.

( Industry Median: 64.74 vs. HSIC: 45.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
HSIC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.01  Med: 40.97 Max: 45.97
Current: 45.97
38.01
45.97
Days Payable 42.21
HSIC's Days Payable is ranked lower than
79% of the 47 Companies
in the Global Medical Distribution industry.

( Industry Median: 68.40 vs. HSIC: 42.21 )
Ranked among companies with meaningful Days Payable only.
HSIC' s Days Payable Range Over the Past 10 Years
Min: 37.11  Med: 42.46 Max: 48.19
Current: 42.21
37.11
48.19

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 2.50
HSIC's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 39 Companies
in the Global Medical Distribution industry.

( Industry Median: -0.90 vs. HSIC: 2.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HSIC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -30  Med: -0.65 Max: 49.5
Current: 2.5
-30
49.5

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 90.47
HSIC's Price-to-Tangible-Book is ranked lower than
96% of the 46 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.82 vs. HSIC: 90.47 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
HSIC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.37  Med: 7.53 Max: 124.17
Current: 90.47
2.37
124.17
Price-to-Intrinsic-Value-Projected-FCF 1.23
HSIC's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
55% of the 29 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.61 vs. HSIC: 1.23 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HSIC' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.76  Med: 1.4 Max: 8.35
Current: 1.23
0.76
8.35
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.24
HSIC's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
67% of the 12 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.33 vs. HSIC: 1.24 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
HSIC' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.47  Med: 1.1 Max: 2.51
Current: 1.24
0.47
2.51
Price-to-Median-PS-Value 1.00
HSIC's Price-to-Median-PS-Value is ranked lower than
72% of the 47 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.95 vs. HSIC: 1.00 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HSIC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.27  Med: 0.88 Max: 1.47
Current: 1
0.27
1.47
Price-to-Peter-Lynch-Fair-Value 2.33
HSIC's Price-to-Peter-Lynch-Fair-Value is ranked lower than
82% of the 17 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.48 vs. HSIC: 2.33 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
HSIC' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.29  Med: 1.89 Max: 3.25
Current: 2.33
0.29
3.25
Price-to-Graham-Number 8.94
HSIC's Price-to-Graham-Number is ranked lower than
97% of the 33 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.57 vs. HSIC: 8.94 )
Ranked among companies with meaningful Price-to-Graham-Number only.
HSIC' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.1  Med: 3.01 Max: 16.71
Current: 8.94
1.1
16.71
Earnings Yield (Greenblatt) % 6.88
HSIC's Earnings Yield (Greenblatt) % is ranked higher than
55% of the 60 Companies
in the Global Medical Distribution industry.

( Industry Median: 5.56 vs. HSIC: 6.88 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HSIC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.8  Med: 8 Max: 16.7
Current: 6.88
4.8
16.7
Forward Rate of Return (Yacktman) % 12.91
HSIC's Forward Rate of Return (Yacktman) % is ranked higher than
54% of the 35 Companies
in the Global Medical Distribution industry.

( Industry Median: 10.23 vs. HSIC: 12.91 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
HSIC' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 10.5  Med: 14.6 Max: 28.4
Current: 12.91
10.5
28.4

More Statistics

Revenue (TTM) (Mil) $12,264.42
EPS (TTM) $ 3.47
Beta1.03
Short Percentage of Float5.77%
52-Week Range $65.28 - 93.50
Shares Outstanding (Mil)156.95

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 12,345 13,124 13,952 14,517
EPS ($) 3.75 3.97 4.39 4.85
EPS without NRI ($) 3.75 3.97 4.39 4.85
EPS Growth Rate
(Future 3Y To 5Y Estimate)
1.62%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}